glp 1 heart disease GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential Glucagon-like peptide 1 receptor agonists:

Manage stress through yoga, meditation, or deep breathing

For instance, in January 2025, the FDA approved semaglutide (Ozempic) as a medication to reduce the risk of kidney failure, kidney disease progression, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD)

Wegovy and Zepbound could both be covered for the treatment of weight loss (an FDA-approved use) but would not be approved for use in treating Type 2 diabetes

Extensive research has consistently demonstrated the effectiveness of semaglutide in improving blood sugar management, reducing the likelihood of cardiovascular issues, and facilitating weight loss

Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial

Notably, his remarkable weight loss journey post-retirement has piqued considerable curiosity, leaving many intrigued about Charles Barkley's transformation